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Abstract: The c-Jun NH2-terminal protein kinase (JNK) is a Janus-faced kinase, which, in the
nervous system, plays important roles in a broad range of physiological and pathological processes.
Three genes, encoding for 10 JNK isoforms, have been identified: jnk1, jnk2, and jnk3. In the developing
spinal cord, JNK proteins control neuronal polarity, axon growth/pathfinding, and programmed cell
death; in adulthood they can drive degeneration and regeneration, after pathological insults. Indeed,
recent studies have highlighted a role for JNK in motor neuron (MN) diseases, such as amyotrophic
lateral sclerosis and spinal muscular atrophy. In this review we discuss how JNK-dependent signaling
regulates apparently contradictory functions in the spinal cord, in both the developmental and adult
stages. In addition, we examine the evidence that the specific targeting of JNK signaling pathway
may represent a promising therapeutic strategy for the treatment of MN diseases.
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1. Introduction
C-Jun NH2-terminal kinase (JNK) is a member of the mitogen-activated protein kinases (MAPKs):
it was discovered more than 20 years ago as the protein kinase family responsible for the transactivation
of c-Jun by phosphorylating the N-terminal Ser-63 and Ser-73 residues [1,2]. Since its discovery,
a wide amount of studies has been conducted to define the molecular complexity of the JNK signaling
pathway in cells. Like the other MAPKs, the activation and increased activity of JNK requires its dual
phosphorylation at Tyr and Thr residues, mediated by MAPKKs namely MKK4 and MKK7, which
consist of a group of protein kinases with different biochemical properties [3,4]: MKK7 acts as a specific
activator of JNK, whereas MKK4 can also activate p38 MAPK; both MKK4 and MKK7 are selectively
regulated by extracellular stimuli and show distinct affinity for JNK [4,5]. MKK4 and MKK7 activation
is in turn mediated by various MAPKKKs (e.g., apoptosis signal-regulating kinases, ASKs; mixed
lineage protein kinases, MLKs; and dual leucine zipper kinase, DLK); moreover the JNK signaling
pathway is also modulated by different scaffold proteins, as the JNK-interacting protein (JIP)1, JIP2,
and JIP3 [6–8].
Three genes, which can be alternatively spliced into 10 isoforms, have been identified: jnk1, jnk2,
and jnk3 [9]. JNK1 and JNK2 expression is ubiquitous, whereas JNK3 is mainly expressed in the brain,
testis and cardiac smooth muscle. Indeed, in most mammalian cell types, JNK activation is strictly
controlled and the protein is recruited at moderate levels and at specific circumstances; in contrast,
JNK signaling in the brain is highly and constitutively activated [10–13], thus suggesting that these
kinases play a role as key regulator of protein function in the nervous system.
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In neurons, JNK signaling is a Janus-faced pathway, which can play a dual role by mediating
either physiological or pathological responses [10,13]. Both anti- and pro-apoptotic signals converge on
activating MKK4–JNK or MKK7–JNK signaling nodes through specific MAPKKKs, thus contributing
to the dual role of this protein family [14]. Moreover, JNKs and the scaffold molecules bind and show
distinct patterns of compartmentalization at the subcellular level (nuclear and cytoplasmic), probably
related to their pleiotropic function (physiological vs. stress-inducible). Indeed, JNKs are not located
statically in a given cellular compartment, but they are able to translocate from the cytoplasm to
the nucleus and vice-versa in response to specific stimuli (as for example, stress and excitotoxicity
signals released in response to hypoxia or ischemic events [15]. In the nucleus, different transcription
factors, such as c-Jun, ATF-2, Elk-1, p53, and NFAT4, which then trigger specific cell stress-responses,
are phosphorylated by JNKs [16,17]. In the cytoplasm, interestingly, JNK has been associated with
vesicular structures, in particular close to mitochondria [18,19]; indeed, after exposure to excitotoxic
stress, JNK is translocated from the nucleus to cytosolic mitochondria, where it can easily phosphorylate
those substrates that are known as initiators of programmed cell death following exposure to noxious
stimuli [20,21].
While on one side JNK family has been described as involved in injury responses and stress-induced
apoptosis in neurodegenerative diseases and, more recently, in the pathophysiology of neuropsychiatric
disorders [22–24], on the other JNKs are also able to influence neuronal differentiation, by directly
targeting chromatin modifiers for modulating histone phosphorylation and acetylation [25]. Therefore,
they are involved in the regulation of transcription of those genes related to brain morphogenesis,
together with those for axonal growth and pathfinding [18].
In the cytoplasm, evidence show that JNKs are able to activate many non-nuclear substrates,
with wide-range functional roles in brain development, such as cell migration, axonal guidance, neurite
formation and outgrowth, and also regeneration of nerve fibers after injury [17,26]. Indeed, studies on
knockout models of each JNK isoform (Jnk1−/−, Jnk2−/−, and Jnk3−/−) have revealed the role of JNKs
in brain development and morphogenesis, together with axodendritic architecture maintenance and
restoration [18,27–29] (Figure 1).
Thus, the studies performed in these years on JNKs and their molecular pathways identified these
molecules as key players in the developing and adult brain, providing the basis for understanding the
multifunctional role of JNK signaling in different conditions, cell types, and life stages.
In this review, we will summarize the involvement of the JNK protein family in neuronal
physiology and pathology, focusing on the spinal cord. We will describe the role of JNKs in healthy
developing and adult nervous system, and in neurodegenerative diseases, with particular attention to
those characterized by progressive motor neuron (MN) depletion.
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Figure 1. JNK signaling pathways and functions in the nucleus and cytoplasm of spinal cord neurons. 
JNK pathways are activated by different anti- or pro-apoptotic signals such as extracellular (e.g., 
inflammatory signals, pathogens, developmental factors, and neurotransmitters) as well as 
intracellular (e.g., oxidative stress, and DNA damage) stimuli that converge on the three JNK isoforms 
and promote JNK pleiotropic functions (physiological vs. stress-inducible): they can translocate in the 
nucleus and in mitochondria, or remain into the cytoplasm. JNKs phosphorylate a variety of 
cytoplasmic as well as nuclear substrates, can trigger the programmed cell death, promote a wide 
range of functional roles in brain development (e.g., cell migration, axonal guidance, neurite 
formation, and outgrowth) and in nerve regeneration. Abbreviations: JNK, c-Jun amino-terminal 
kinase; MKK4/7, mitogen-activated protein kinase kinase 4/7; PCD, programmed cell death, TFs, 
transcription factors. 
2. JNK in CNS Development 
Experimental knockout and knockdown approaches in vivo demonstrated that JNKs are 
functionally active in different stages of brain development: thus, alterations of this molecular 
pathway can lead to various developmental defects [18]. JNKs are activated following neurulation, 
when cell proliferation and migration phases are ongoing, and are involved in different 
developmental processes generally related to axo-dendritic architecture formation and stabilization, 
and to neuronal pathfinding (Figure 2). 
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2. JNK in CNS Development
Experimental knockout and knockdown approaches in vivo demonstrated that JNKs are
functionally active in different stages of brain development: thus, alterations of this molecular
pathway can lead to various developmental defects [18]. JNKs are activated following neurulation,
when cell proliferation and migration phases are ongoing, and are involved in different developmental
processes generally related to axo-dendritic architecture formation and stabilization, and to neuronal
pathfinding (Figure 2).
Cells 2019, 8, 1576 4 of 24
Cells 2019, 8, x 4 of 24 
 
 
Figure 2. JNK roles in development. JNK signaling pathway is involved in axo-dendritic architecture 
formation and stabilization. Phosphorylation of JNK and its specific targets leads to dendrite (A) and 
axon (B) determination, thus contributing to neuronal polarity definition. (C) In developing spinal 
cord, JNK is required for axonal pathfinding of both commissural and motor axons. Abbreviations: 
JNK, c-Jun amino-terminal kinase; MAP, microtubule associated protein; Sema3a, semaphorin3a; 
BMPR, bone morphogenetic protein receptor; NRP, neuropilin; TAOK2, thousand-and one amino 
acid kinase 2; EcRB1, ecdysone receptor B1; DLK, dual leucine zipper kinase; MKK4/7, mitogen-
activated protein kinase kinase 4/7; PPARγ, Peroxisome Proliferator-Activated Receptors-γ; ARP, 
actin-related protein; GAP43, growth associated protein 43; NF, neurofilament; DSCAM, down 
syndrome cell adhesion molecule; DCC, deleted in colorectal cancer; MNs, motor neurons. 
2.1. JNK Role in Dendritogenesis 
JNK molecules are involved in dendrite architecture regulation and dendrite pruning, which are 
crucial events for the formation of precise neuronal connections (Figure 2A). Although the specific 
mechanisms remain to be completely addressed, JNK is thought to act on dendrite morphology by 
phosphorylating the microtubule-associated proteins 1 and 2 (MAP1 and MAP2) targets, specifically 
in the dendritic compartment. Indeed, Jnk1–knockout mice show a reduction in phospho-MAP1 and 
MAP2 in the brain: cerebellar granule neurons isolated from these mice display an increased dendrite 
complexity, with a higher dendrite number compared to wild-types and reduced dendritic length 
[18,27,30], suggesting an impairment in microtubule integrity. 
Extrinsic factors are also able to phosphorylate JNK signaling, by receptor-mediated activation, 
to modulate dendritic architecture. For instance, the bone morphogenetic protein receptor II 
(BMPRII) and the non-canonical WNT pathway activation can increase dendrite complexity via JNK 
[31,32]. Moreover, the secreted guidance cue semaphorin 3A (Sema3A) acts via the neuropilin 1 
receptor and thousand-and one amino acid kinase 2 (TAOK2) molecule to activate JNK signaling at 
least in cortical neurons [18,33]. Recently, Zhu and colleague identified a novel mechanism involving 
JNK signaling dendrite pruning in Drosophila (c4da) neurons, which are characterized by a drastic 
remodeling during the metamorphosis: in this model, JNK coordinates with ecdysone receptor B1 
(EcRB1) to specifically activate the expression of the downstream Fos protein since the early pupal 
stage, suggesting that ecdysone signaling provides temporal control of dendritic pruning regulation 
by JNK signaling. Loss of JNK or its canonical downstream effectors Jun or Fos led to dendrite-
Figure 2. JNK roles in development. JNK signaling pathway is involved in axo-dendritic architecture
formation and stabilization. Phosphorylation of JNK and its specific targets leads to dendrite (A) and
axon (B) determination, thus contributing to neuronal polarity definition. (C) In developing spinal cord,
JNK is required for axonal pathfinding of both commissural and motor axons. Abbreviations: JNK,
c-Jun amino-terminal kinase; MAP, microtubule associated protein; Sema3a, semaphorin3a; BMPR,
bone morphogenetic protein receptor; NRP, neuropilin; TAOK2, thousand-and one amino acid kinase 2;
EcRB1, ecdysone receptor B1; DLK, dual leucine zipper kinase; MKK4/7, mitogen-activated protein
kinase kinase 4/7; PPARγ, Peroxisome Proliferator-Activated Receptors-γ; ARP, actin-related protein;
GAP43, growth associated protein 43; NF, neurofilament; DSCAM, down syndrome cell adhesion
molecule; DCC, deleted in colorectal cancer; MNs, motor neurons.
2.1. JNK Role in Dendritogenesis
JNK molecules are involved in dendrite architecture regulation and dendrite pruning, which are
crucial events for the formation of precise neuronal connections (Figure 2A). Although the specific
mechanisms remain to be completely addressed, JNK is thought to act on dendrite morphology by
phosphorylating the microtubule-associated proteins 1 and 2 (MAP1 and MAP2) targets, specifically
in the dendritic compartment. Indeed, Jnk1–knockout mice show a reduction in phospho-MAP1
and MAP2 in the brain: cerebellar granule neurons isolated from these mice display an increased
dendrite complexity, with a higher dendrite number compared to wild-types and reduced dendritic
length [18,27,30], suggesting an impairment in microtubule integrity.
Extrinsic factors are also able to phosphorylate JNK signaling, by receptor-mediated activation,
to modulate dendritic architecture. For instance, the bone morphogenetic protein receptor II (BMPRII)
and the non-canonical WNT pathway a tivation c n increase dendrite complexi y via JNK [31,32].
Moreover, the secreted guidance cue semaphorin 3A Sema3A) acts via the neuropilin 1 receptor and
thousand-and one ami o acid kinase 2 (TAOK2) molecule to activat JNK signaling at least in cortical
neuron [18,33]. R cently, Zhu and colleague identified a novel mech nism involving JNK signaling
dendrite pruning i Drosophila (c4da) neurons, which are characterized by a drastic remodeling during
the metamorphosis: in this model, JNK coordinates with ecdysone receptor B1 (EcRB1) to specifically
activate the expression of the downstream Fos protein since the early pupal stage, suggesting that
ecdysone signaling provides temporal control of dendritic pruning regulation by JNK signaling. Loss
of JNK or its canonical downstream effectors Jun or Fos led to dendrite-pruning defects in c4da neurons.
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Furthermore, Wnt5 signaling seems to be required for the regulation of dendritogenesis in Drosophila
neurons and genetically interacts with JNK signaling pathway [34].
2.2. JNK Role in Axonogenesis
The activation of JNK is required for axon formation, thus being important for the acquisition of
neuron polarity [35]. Indeed, JNK is expressed throughout the neurons, but its phosphorylated form is
highly enriched in axons, where it is expressed in a distally directed gradient of increasing intensity,
until the growth cone. During axonogenesis, the expression of phospho-JNK in the developing axon is
increased about seven folds above the average intensity of the minor processes [35] and this increased
phosphorylation reaches the highest level when the axon surpasses the “critical length”, i.e., the extent
that unequivocally identifies a process as an axon, compared to the other neurites [36]: this suggests
that JNK activation is an early event in axon formation. Transection (e.g., axotomy) proximal to the
critical length leads to the loss of neuronal polarity and the possible formation of a new axon from a
different site; conversely, when the axon is transected beyond the critical length, it is able to regenerate
and maintain the polarity. Thus, it is possible that transection leading to the polarity loss would
reduce or eliminate the activated JNK proteins present in the axon [37]. Treatment with specific JNK
inhibitors, or with dominant-negative constructs targeting JNK, are able to reversibly but selectively
inhibit axonogenesis, because they do not prevent the formation of the minor/shorter processes and
their differentiation into dendrites [35,38]. Besides JNK, a member of another MAP kinase subfamily,
p44/p42 extracellular signal-regulated kinase (ERK1/2), has also been implicated in neurite outgrowth
and in the development of neuronal polarity [35,39].
During axonogenesis, JNK seems to be placed to regulate axonal growth directly, via its effects
on the cytoskeleton, and by regulating transcription over the long term. Indeed, as reported above,
JNK phosphorylates a variety of nuclear and cytoplasmic targets, including transcription factors,
microtubule-associated proteins, and proteins directly interacting with the actin cytoskeleton [30].
Thus, the interaction between JNK and the cytoskeleton-related proteins plays a significant role in
microtubule and actin dynamics for channelling the growth of the emerging axon. For instance, one
substrate related to JNK pathway is the cyclic AMP-dependent transcription factor ATF-2, a member
of the ATF/CREB (cAMP response element-binding protein) family of transcription factors that bind
to CRE (cAMP-responsive element) consensus sites [40]. Once phosphorylated by JNK, ATF-2 is
likely to lead to transcriptional changes that provide the materials necessary for axonal elongation
and maintenance. In fact, the co-expression of c-Jun (JNK phosphorylation substrate) and active
ATF-2 is increased in those retinal ganglion cells that survive after partial optic nerve injury and
restore or partially maintain axonal connection after axotomy. Phospho-ATF-2 is enriched in the
axon, similarly to phospho-JNK. Chronic or acute treatment with inhibitors decreases phospho-ATF-2,
without affecting total ATF-2 levels. Thus, JNK is able to regulate axonal growth directly, via its effects
on the cytoskeleton, and over the long term, by regulating transcription [41] (Figure 2B). In Xenopus
laevis embryos, Hutchins and Szaro identified a post-transcriptional mechanism in which JNK regulates
axonogenesis in spinal motor axons by phosphorylating a specific site on heterogeneous nuclear
ribonucleoprotein K (hnRNP K). JNK phosphorylation of hnRNP K occurs within the cytoplasm
and through phosphorylation of hnRNP K, JNKs posttranscriptionally regulate cytoskeletal genes
that build the axon (e.g., type IV NFs, tau, ARP2, and GAP43). Indeed, JNK phosphorylation of
hnRNP K affected neither nucleocytoplasmic localization nor RNA binding of hnRNP K but rather
mediated the interaction between hnRNP K and the molecular machinery for translating its targeted
RNAs, contributing to regulate translation of proteins crucial for axonogenesis. Both JNK inhibition
and hnRNP K knockdown inhibited motor axon outgrowth and translation of hnRNP K-regulated
cytoskeletal RNAs (tau and neurofilament medium) [38]. Finally, molecules able to phosphorylate
JNK are involved in axonal growth. For instance, the peroxisome proliferator-activated receptor-γ
(PPARγ) is able to stimulate axonal growth and accelerate neuronal polarity on different neuronal cell
types via activation of JNK proteins. Indeed, PPARγ is selectively activated by thiazolidinediones
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(TZDs) drug, leading to the induced activation of the JNK pathway and promoting axonal elongation.
The pharmacological blockage of this pathway prevents axon elongation induced by TZDs [42].
3. JNK in Developing Spinal Cord
After leaving the cell body, the axons manage to find their way following very precise—sometimes
really long—paths in the nervous system, to reach their proper targets. Together with their role
in regulating axonal outgrowth, JNK proteins are also required for axon guidance during CNS
development. Indeed, it has been demonstrated that JNK molecules are activated by different guidance
cues involved in axon pathfinding of different neuronal cell types [32,43], and required for maintaining
the correct axonal trajectories, probably by both phosphorylating cytoskeletal targets and regulating
gene expression [18]. Mice presenting genetic deletion of JNK-pathway components show axonal
anomalies. For instance, the anterior commissure of Jnk1knockout mice degenerates starting from
postnatal day (P)6 to P12, demonstrating that JNK1 is required for axon maintenance [10]. In the
spinal cord JNK is also involved in the regulation of axonal pathfinding processes of different neuronal
subtypes (Figure 2C).
3.1. JNK in Commissural Axons
In the developing spinal cord, the subpopulation of commissural axons projects firstly along
the dorso-ventral axis towards the ventral midline and turns either anteriorly or posteriorly along
the longitudinal axis after crossing the floor plate to the contralateral side. As early as E11, JNK
regulates axonal pathfinding in spinal commissural neuron. The floor plate region is a source of both
chemo-attractant and repellent cues, such as Netrin-1 and Slits [44], that are able to modulate the
axon guidance process. According to the current models, the cell sensitivity to repellents released
by the floor plate is silenced in those commissural growth cones that are pre-crossing the midline,
while is switched-on in the post-crossing commissural growth cones, once expelled from the midline,
in order to avoid them to re-crossing the floor plate. Post-crossing axons are then following the
rostro-caudal gradients of guidance cues and turn caudally or rostrally in the lateral and ventral
funiculi respectively [44,45].
JNK pathway is, indeed, required for netrin signaling in the developing nervous system.
The guidance cue Netrin-1 increases JNK1—not JNK2 or JNK3—activity to enable midline crossing
through a mechanism involving the cell adhesion receptors DCC (deleted in colorectal cancer) or
DSCAM (Down’s syndrome cell adhesion molecule), the main mediators of netrin attraction in the
nervous system [43,46]. In the developing spinal cord, phospho-JNK is highly expressed in commissural
axons before and as they cross the floor plate, and Netrin-1 stimulation dramatically increases the
level of endogenous phospho-JNK in commissural axon growth cones. In vivo, inhibition of JNK
signaling by selective pharmacological inhibitors (e.g., SP600125) or JNK1 RNA interference (RNAi)
is able to suppress Netrin-1-induced axon attraction. JNK1 knockdown during embryogenesis (by
chicken in ovo electroporation) leads to defects in spinal cord commissural axon projection and
pathfinding; while in vitro expression of the JNK1 construct rescues the defects of JNK1 knockdown on
Netrin-1-induced axon outgrowth and attraction. The knockdown of JNK2 and JNK3 does not affect
Netrin-1-induced neurite outgrowth and pathfinding, confirming that the mechanism is mediated only
by JNK1 isoform [43]. Either Netrin-1 knockout or DCC-knockout mice show a defective projection of
commissural axons [47,48]. In vitro, Netrin-1 increases endogenous JNK activity in primary neurons
and its effect is inhibited either by JNK-, JNK signaling-, and DCC-function inhibitors (anti-DCC
function-blocking antibody). The knockdown of DSCAM protein partially inhibits Netrin-1-induced
JNK activation, while, if combined with the anti-DCC function blocking antibody, leads to a total
abolishment of the Netrin-1 effect on JNK activity; thus, DCC cooperates with DSCAM through
regulating JNK activity in Netrin signaling [43].
It has been demonstrated that the axon formation in neurons depends also on stage-specific
regulation of microtubule stability by the dual leucine zipper kinase (DLK), a MAPKKK for JNK.
Cells 2019, 8, 1576 7 of 24
Together with JNK, the DLK-JNK1 pathway facilitates axon formation, plausibly involving also Netrin-1
signaling [43,49].
Moreover, during floor plate crossing, commissural growth cones gain Wnt-Frizzled (glycoproteins
secreted by the ventral midline cells in the floor plate and expressed in an antero-posterior gradient)
signaling responsiveness, which is required for anterior turning of the most dorsal populations of
post-crossing commissural axons [45]. Wnt-Frizzled signaling plays a fundamental role in spinal cord
development and function by activating several pathways [50]. Among those, the highly conserved
planar cell polarity (PCP) pathway has been demonstrated to be involved in Wnt-mediated axon
guidance because of its ability to regulate the polarized cellular and tissue morphology in response to
environmental cues [46,50]. PCP signaling is expressed in commissural axons and leads to the activation
of JNK and c-Jun by phosphorylation [46,51]. Indeed, in commissural axons, Shaffer and colleagues
demonstrated a co-immunoreactivity between phosphor-JNK and TAG-1, a component of the PCP
pathway expressed in pre-crossing and crossing segments of the spinal cord. Phospho-JNK is especially
enriched in the post-crossing segment in a spatio-temporal way (starting from E11). Wnt5a stimulation
in vitro and in “open-book” preparation assays leads to PCP and consequent JNK activation, resulting
in the regulation of spinal cord commissural axon guidance in the antero-posterior direction at the
proper stage when commissural axons are making anterior turning decisions (E13 in rat). Inhibiting
JNK activity leads to antero-posterior randomization of commissural axon trajectories of more than 60%
of commissural axons, especially after midline crossing [46]. Therefore, JNK plays as a downstream
effector of PCP signaling in regulating the antero-posterior guidance of commissural axons.
3.2. JNK in Motor Neuron Development
In the mouse spinal cord, MNs are generated around E9.5 from ventral domain progenitors
of the ventricular zone [52]. MN cell bodies are prevented to leave the spinal cord by so-called
boundary cap cells, which surround nerve roots and express repulsive factors [44], whereas MN
axons extend from the floor plate to reach the proper exit point, where they go through the basal
lamina and leave the spinal cord ventrally, to innervate the skeletal muscles [53]. The cellular and
molecular mechanisms regulating the motor axon to breach the central-peripheral nervous system
boundary, together with the capability of motor axons to reach the proper muscle targets, are still
elusive. A spatial relationship exists between the position of MN cell body in the spinal cord and the
trajectory of the axonal projection to peripheral muscle target [54]; moreover, newborn MNs express a
variety of receptors and signaling molecules, which provide guidance cues for MN axons, including
the Netrin-1 receptors DCC. Furthermore, there are some insight into the mechanisms of axonal rostral
turning, which involves Wnt proteins and SHH [44]. Thus, giving that at least some molecular pattern
expression in developing MN axons are shared with the commissural axons, we could speculate that
also in this cell population, JNK phosphorylation is mediated by Netrin-1 and/or Wnt signaling to
control MN axon pathfinding within and outside the spinal cord, acting at different multiple levels
and by an intertwined manner. For instance, DCC and Netrin-1 knockout mice show defects in MN
pathfinding: the exit point of the axons of ventral MNs is shifted dorsally, indicating that Netrin-1
normally guides axonal elongation ventrally [44,55].
3.3. JNK in Spinal Cord Patterning
Interestingly, the JNK pathway is involved in brain final patterning and neuronal cell number
regulation. The double full knockout mice for Jnk1 and Jnk2 show a failure to complete neural tube
closure, displaying an overt exencephaly phenotype, together with region-specific alterations in cell
survival, with decreased apoptosis in the hindbrain neuroepithelium and increased apoptosis in the
forebrain [18,56].
During brain development, programmed cell death (PCD) occurs as a controlled mechanism for
the maintenance of the homeostasis and tissue integrity. The activation of JNK-c-Jun signaling is a
crucial event for the PCD of neurons, including MNs; indeed, it has been shown that JNK-mediated
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c-Jun phosphorylation is a transient and reversible event that occurs when a MN is more dependent on
survival signals (e.g., neurotrophic factors) than in the adult.
In vitro, the overexpression of c-Jun is able to induce neuronal cell death, that can be prevented
by the dominant-negative Jun; moreover, the co-expression of the dominant negative-Jun with the
JNK- blocking JBD domain of JIP1 is involved in the same pathway in JNK/c-Jun mediated cell death.
Rescue from PCD by deletion of pro-apoptotic genes, such as the Bax gene, leads to inhibition
of c-Jun signaling and subsequent reduction in MN death. In vivo, data confirm the necessary,
but not sufficient, involvement of JNK downstream protein c-Jun in the commitment to die:
the phosphorylation of c-Jun was observed in MNs during embryonic PCD, and actions increasing
cell survival (e.g., neuromuscular activity blockade) reduce the number of the phospho-c-Jun positive
MNs [57,58]. Thus, in the embryo, JNK-c-Jun cascade seems to be important for the initiation of early
and reversible mechanisms of PCD, if the survival-promoting signals are not sufficient or lacking [59].
Pharmacological inhibition of c-Jun upstream inducers- such as JNK and p38 kinases- also promotes the
survival of embryonic motor, sensory, and sympathetic neurons [58,60,61]. Thus, JNKs are functional
in various stages of spinal cord development and are required in different cell populations to provide
the proper axonal position and PCD.
The dual role for JNK in CNS development, in promoting the outgrowth and differentiation
of cellular components, together with regulating cell number via programmed cell death, has been
observed also in the adult nervous system. Thus, the second part of the review will highlight the main
functions of JNK pathway in both regeneration and degeneration conditions in adult spinal cord.
4. JNK in Adult CNS
JNK in Axonal Degeneration and Regeneration
Among neuronal compartments, axons are highly specialized structures that require integrity and
maintenance throughout their entire lifespan. After development, the normal functions of central and
peripheral axons can be compromised by various insults such as trauma, demyelination, blockade
of axonal transport, chemical toxicity as well as diseases, leading to progressive morphological and
molecular changes in response to stress (e.g., swelling of the cell body and fragmentation of rough
endoplasmic reticulum). As a consequence of axonal lesion (axotomy), the neuron triggers its axonal
self-destruction program, probably due to the loss of maintenance factors, which result in cytoskeletal
disassembly and granular degeneration of the axon distal to the injury site, toward the cell body [62].
Depending on the context, axonal injury can result in neuronal apoptosis, axonal degeneration
and/or regeneration, and JNK is required for triggering each of these different responses (Figure 3).
In adulthood, neuronal death is an evident and rapid event after axotomy of central “intrinsic”
neurons (neurons projecting within the CNS districts) and less prominent and delayed following
axotomy of those central “extrinsic” cells whose axons project into the periphery (e.g., MN axons and
cranial nerves) [19].
It has been demonstrated that JNK pathway triggers neuronal degeneration and death in different
brain pathological conditions and diseases, such as ischemia [63], epilepsy [64], and Alzheimer’s
disease [65], strongly suggesting the pro-apoptotic role of JNK pathway also after axon injury.
For instance, alterations of JNK and p38 signaling pathways have been observed in vitro and in vivo
as potentially associated with pathogenesis and neuronal apoptosis in Alzheimer’s disease [66].
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Crushing r cutting the perip eral n rves represent the xperiment l m del f choice to study the
cellular and m lecular mechanisms of axotomy-indu ed neuronal death and rei nervation. Indeed, it
has been dem nstrated that degeneration b th fter ne v injuries and axon pruning share several
molecular pathways [67]. Among those molecules, JNK activation is associated with both neuronal
death and regeneration, showing its dichotomy.
In adult CNS, indeed, the JNKs are involve in triggering cell death in different cell types and the
expression of dominant negative inhibitors of nuclear JNK c nfers resistance to the apoptotic events
following trophic support. JNK can modulate death signaling t rough the cano ical phosphorylation of
c-Jun pathway: it is of note that the non-phosphorylable cell mutants of c-Jun are resistant to apoptosis,
and c-Jun deficiency results in resistance to axotomy-induced death [19]. Moreover, alternative
pathway mediate JNKs contribution to c ll death: some of th m involve the phosphorylation of the
p53 family proteins [14], others involve different cytoplasmi (e.g., Bcl-2, Bcl-X, and Bim) a d nuclear
substrates (e.g., ATF2; and Elk-1) that m diate JNK effects [68,69].
The extent of involvement of c-Jun or other nuclear/cytoplasmatic molecule in JNK-mediated
regulation of axotomy-induced cell death s ill remains to be elucidated (Figure 3A). JNK signaling
recruitment changes pending on cell types an conditions, as neuronal differ nt populations can
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exhibit distinct temporal differences in the regulation of cell death, highlighting that the vulnerability
of neuronal subtypes is specific. Moreover, the three isoforms and substrate-specific functions of JNK
molecule add an additional level of complexity [69]. Indeed, JNK role in pro-apoptotic mechanisms is
mediated by both cell type and time, as a lack of JNK2 and JNK3 isoforms in facial MNs significantly
reduces their axotomy-induced death in neonatal mice, whereas death of adult facial MNs seems
independent by JNKs [70,71], suggesting a developmental modulation of JNK actions in these neurons.
In other cell types—as nigrostriatal dopaminergic cells of the medial forebrain bundle—JNK
promotes neuronal cell death mainly by phosphorylation of c-Jun downstream protein. Indeed,
axotomy leads to a JNK3-dependent death of nigral neurons, and JNK3-deficient mice show enhanced
and lasting survival of the axotomized dopaminergic neurons in the substantia nigra pars compacta [70].
In Purkinje cells, for example, c-Jun deficiency results in resistance to axotomy-induced death, while the
overexpression of c-Jun enhances the death of injured cells [72], thus suggesting also a cell type-specific
function of JNK-c-Jun mechanisms in both repair and death events.
The stress-activated MAPK pathways are also involved in the transmission of apoptotic signals
following traumatic spinal cord injury (SCI): for instance, SCI leads to early ASK1 activation in both
white and grey matters and subsequent phosphorylation of JNK and p38 MAPK observed in apoptotic
cells [73]. Indeed, JNK contributes to trauma-induced DP5 expression and subsequent neuronal
apoptosis mediated by c-Jun phosphorylation, and in vivo inhibition of JNK activity attenuates
DP5 induction and caspase-3 activation, resulting in cell protection [74]. Moreover, JNK inhibition
by peptide administration shows neuroprotective effects by preventing c-Jun phosphorylation and
caspase-3 cleavage, resulting in an increased sparing of white matter at the spinal lesion site, pointing
out that JNK inhibition could prevent the evolution of secondary damage after spinal cord injury [75].
Thus, JNK has been identified as a key element responsible for the regulation of apoptotic signals and
therefore, it is critical for pathological cell death also following SCI.
Oxidative stress is also responsible of MN death by apoptosis in the spinal cord. Oxidative stress
occurs when the production of the oxidizing agents overwhelms the normal antioxidant capacity
system of the cells. This is detrimental to MNs and finally leads to neuronal cell death due to the reactive
oxygen species (ROS) accumulation and mitochondrial dysfunctions (mitochondrial uncoupling and
membrane depolarization). Indeed, after spinal cord injury, MN death could occur by oxidative stress
through cytochrome C release [76]. It has been reported that oxidative stress in MNs in vitro induces
the increase in expression levels of phosphorylated JNK proteins [76], and decreases the activation of
other kinase molecules (such as ERK1/2) reported to promote cell survival [77].
Pharmacological intervention with molecules, which protect cells from oxidative stress
damage—e.g., Midazolam—decreases the expression levels of phospho-JNK in MN cell lines while
it leads to the increasing expression levels of anti-apoptotic kinases, promoting cell survival [78].
Other papers highlight the dual role of JNK pathway in promoting both MN degeneration and
regeneration. Indeed it has been shown that in MN depleted of trophic factors, JNK inhibition attenuates
caspase activation, nuclear condensation, and reduces cell death. Conversely, pharmacological JNK
inhibition in healthy MNs supplied with trophic factors results in a decreased mitochondrial membrane
potential, decreased phosphorylation of cytoskeletal MAP1 proteins, leading to cell degeneration [69].
JNK signaling is also involved in Wallerian degeneration, which occurs in the neuron at the site of
the lesion without affecting the cell body viability, in absence of neuronal death [79,80] (Figure 3B).
The axon degenerates in 3–4 days through a process of swelling and subsequent granulation, together
with myelin. JNKs play a central role in Wallerian degeneration and subsequent regeneration. The JNK
pathway is required for regulating axonal degeneration early after injury, before axon fragmentation.
Indeed, the inhibition of JNK soon after injury is able to delay the ongoing degeneration, whereas
inhibition starting during axonal fragmentation phase shows no effect [81]. The molecular mechanisms
mediating JNK regulation of Wallerian degeneration remain partially unknown. JNK signaling after
injury requires the orphan receptor death receptor 6 (DR6) to drive axon degeneration by further
activation of calpains, as observed both in vitro and in vivo [82]. JNK phosphorylation after axonal
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damage dramatically decreases SCG10 affinity for tubulin, altering the balance between microtubule
assembly and disassembly, and leading to SCG10 depletion and accelerated axonal degradation [83,84].
The pro-degenerative signaling promoted by JNK in axons can be blocked by the Wallerian degeneration
slow (WldS) protein activation, whose function is carried out through chaperone activity, at least in
Drosophila models of axonal injury [85].
Axotomy leads to a fast and lasting JNK accumulation in the axotomized perikaryon (JNKs
are retrogradely transported from the site of injury to the perikaryon), also characterized by the
persistent phosphorylation of c-Jun in its N-terminal, which is a cellular response conserved in neurons.
The accumulation of JNK might label those neurons prone to die. Inversely, the presence of activated
JNK in axonal sprouting indicates that the pathway is involved in regenerative efforts to reconnect the
neuron-target axis. Indeed, JNK activation is sustained during regeneration and return to basal levels
once the process is completed [19] (Figure 3C). For instance, the Jnk1 knockout mouse shows a delay in
axonal regeneration after facial nerve cut [86].
Interestingly, not all the three JNK isoforms play the same role in regeneration. Indeed, loss of JNK2
and JNK3 (and not JNK1) delays neuritogenesis in vitro and in vivo, suggesting their specific roles in
either initiation or extension of regenerating neurites. JNK signaling is further required for promoting
neurite elongation, as pharmacological JNK inhibition results in neurite retraction; this activity relies on
JNK1 and JNK2 and not on JNK3. Moreover, in the cytoplasm, JNK1 and JNK2—but not JNK3—regulate
the phosphorylation state of the microtubule-associated protein MAP1B, whose role in guiding the
directionality of growth cone migration and axonal branching in regeneration has been proved. Indeed,
a lack of MAP1B prevents neurite retraction induced by JNK inhibition [87,88]. Thus, different JNK
isoforms show different implications in cytoskeletal reorganization leading to axon regeneration.
In the cell body, JNKs trigger both expression and activation of c-Jun downstream molecules;
indeed, c-Jun is essential for triggering JNK effects on regeneration. In the CNS, the c-Jun depletion
is correlated with the failure in axonal pruning, whereas its presence is related to the regrowth of
axotomized neurons following spinal cord hemisection. Thus, the available data highlight that most of
the neurons that survive axotomy and maintain the competence to regenerate the axons, also exhibit
an early and lasting expression of c-Jun [19,89,90].
A further mechanism contributing to axonal regeneration is the stimulation of the receptors for
cytokines or growth factors. Interestingly, at least in Caenorhabditis elegans, it has been demonstrated
that, after axonal injury, the binding between the growth factor SVH-1 and its receptor tyrosine kinase,
SVH-2, modulates the activation of the KGB-1 JNK-MAPK cascade to promote regeneration. Loss or
deficiency in SVH-1-SVH-2 signaling leads to the impairment of neurons in regeneration capability.
This event, moreover, seems to be peculiarly related to neuron regeneration processes, whereas it is not
involved in neuronal development [91].
Apart from nuclear c-Jun, JNK proteins can phosphorylate also different proteins in the cytoplasm,
like neurofilaments and STAT3, to regulate the axonal growth [19,92,93]. For instance, JNKs and STAT3
show a similar activity pattern, and STAT3 plays a similar role of JNK in regeneration after axotomy,
as MNs of STAT3-knockout mice are more likely to undergo cell death than those of wild-type mice,
implying a cooperation between JNK and STAT3 proteins to promote axonal outgrowth [94,95].
Determining the factors contributing to the dual role of JNK as a regulator of both regeneration and
neuronal death remains an open question. Even though all JNK proteins are involved in neuritogenesis,
whereas JNK2 and JNK3—and not JNK1 isoform—are more likely to mediate programmed cell death,
it is difficult to address if a specific JNK isoform displays a pivotal role in degeneration and/or
regeneration: indeed, the majority of experiments related to axotomy are performed in vitro, in order to
easily gain insight into axon severing and into signal transduction mechanisms; however, this leads to a
limited view of all the intrinsic cellular “states” of a neuron and the extracellular molecular environment
that could be present in the brain parenchyma after axonal damage. Cytoskeletal alterations and local
changes due to axonal cut could promote local JNK activation: JNK could be then involved in either
the phosphorylation of cytoplasmic proteins for promoting axonal regrowth, or in the activation of
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genes in the nucleus for activating cell death signaling [96]. Thus, it is presumable that the Janus-faced
characteristic of JNK in the brain depends on JNK upstream activators and/or downstream effectors
that could steer JNK signaling in the regenerative/degenerative directions. For instance, p38 and JNK
pathways are able to promote axon regeneration when they are coordinately activated, and axonal
regeneration fails if the activity of either pathway is absent. The synchronized regulation of these two
MAPK pathways is mediated by the E3 ubiquitin ligase Phr1 via selective and targeted degradation of
the MAPKKKs DLK-1 and MLK-1 and by the MAPK phosphatase MKP7, which downregulates both
p38 and JNK as observed in C. elegans, on JNK pathway molecule homologues [97]. The upstream
cascades are also not so clearly understood. For instance, the dual leucine zipper kinase (DLK) seems
to control the contradictory response of JNK signaling in mammalian neurons. Indeed, under certain
circumstances, DLK interacts with JIP3 proteins and the mitogen-activated protein kinase kinase 7
(MKK7) to lead to JNK phosphorylation and trigger c-Jun and caspase signaling activation, to promote
neurodegeneration and cell death. Conversely, DLK can activate MKK7 and MKK4 to promote JNK
activation by phosphorylation in Wallerian degeneration processes. Indeed, after activation, JNK can
bind SCG10 to increase axon degradation, and the involvement of JIP proteins in this mechanism
remains to be elucidated. Finally, the DLK-dependent phosphorylation of JIP3 and MKK7 and MKK4
can also direct JNK activity towards specific neuronal responses (e.g., transcriptional activation of
ATF3, Sprr1a, and Klf6 genes), leading to axon regeneration [98,99]. To sum up, JNKs exert different
functions in response to axonal injury, supporting both degeneration and regeneration. Understanding
the upstream and downstream pathways involved in pro/anti-survival JNK recruitment would be
of considerable importance in the perspective of acting on JNK pathway on one side to counteract
degeneration and, on the other, to promote neuronal regeneration.
5. JNK in MN Degenerative Diseases
JNKs elicit neuronal death in a wide range of pathological contexts, characterized by axotomy
or other type of cell excitotoxic insults, which lead to stress response activation in neurons [18].
Among these diseases, those affecting MNs are characterized by abnormalities of cytoskeletal
regulation, especially at the axonal level, including neurofilament accumulation [100], oxidative
stress sensitivity [101], and dysfunctions followed by a neurodegeneration induced by inflammatory
agents and loss of trophic support [102]. All these insults can promote progressive cell death; moreover,
evidence from animal models suggests that the neuronal dysfunctions precede the clinical phase of
these diseases. Indeed, MN diseases are characterized by a partial degradation of nerve terminals
and neuromuscular junctions at the early stages, while most cell bodies remain intact. MN pathology
seems to initiate at the distal axon terminals—determining a loss of motor units and associated muscle
functions—and to proceed in a “dying-back” pattern up to the cell body [103,104]. Therefore, one
should focus on MN axons and terminals to study pathways involved in progressive MN degeneration,
in order to delay or prevent neuronal degradation and death. Given the involvement of JNK molecules
in degeneration and regeneration processes in neurons, this pathway is likely also involved in MN
diseases. Thus, we will focus on JNK roles in three different pathologies affecting MNs: amyotrophic
lateral sclerosis (ALS), commonly diagnosed in middle and late adulthood, spinal muscular atrophy
(SMA), which occurs in early childhood (Figure 4), and the spinal and bulbar muscular atrophy,
an adult-onset disorder characterized not only by the degeneration of spinal MNs, but also of those in
the brainstem.
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Figure 4. JNK involvement in motor neuron diseases. MN diseases are characterized by a partial
degradation of nerve terminals and motor neuron junctions at the early stages. Within these MN
pathologies, a role of JNK pathway has been demonstrated in amyotrophic lateral sclerosis (A) and spinal
muscular atrophy (B). Abbreviations: MNs, motor neurons; NMJ, neuromuscular junctions; JNK, c-Jun
amino-terminal kinase; MKK4/7, mitogen-activated protein kinase kinase 4/7; DLK, dual leucine zipper
kinase; TNFα, tumor necrosis factor alpha; TAK1, transforming growth factor beta-activated kinase 1;
MEKK-1, mitogen-activated protein kinase kinase kinase-1; ASK1, apoptosis signal-regulating kinase1.
5.1. JNK Role in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting both upper
and lower MNs [105]. Approximately 90% of ALS cases are sporadic (sALS), whereas the remaining
10% are familiar (fALS) cases, with mutati ns identified in greater than 20 gen s (including SOD1,
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TARDBP, FUS, and C9ORF72) across varies cellular functions; these mutations contribute for the
two-third of fALS and for about the 10% of sALS [106]. However, sALS and fALS share a variety
of complex and correlated pathological mechanisms that contribute to MN malfunction and death,
including mitochondrial dysfunction, neuroinflammation, excitotoxicity, and protein aggregation [107].
This makes ALS a heterogeneous and multifactorial disease and explains the present lack of an effective
treatment for all forms. Among the molecular mechanisms underlying ALS onset and progression,
also JNK seems to play a role: given its function in cellular response to stress and activation of the
canonical apoptotic pathway, the involvement of JNK signaling pathways in ALS disease seems to be
ascertained (Figure 4A).
It has been shown that the mitogen-activated protein kinase MAP4K4 signaling results upregulated
in stressed MNs derived from SOD1G93A mice (the most common used ALS experimental model).
MAP4K4 can be activated by TNFα and, in turn, it activates TAK1 and MKK4/MKK7 proteins, leading
to the phosphorylation of JNK and, ultimately, c-Jun. Indeed, suppression of MAP4K4 by short
interfering RNA (siRNA) silencing in both SOD1-mutant mice and human SOD1-mutant iPS-derived
MNs improves cell survival and neurite outgrowth, indicating that the pro-MN survival by MAP4K4
inhibition is conserved across species. Additionally, these experiments highlighted that JNK3 (rather
than JNK1 and 2) is the active isoform mediator of cell death via MAP4K4 activation. Indeed, using
both MAP4K4 and JNK3 siRNA simultaneously do not lead to any increased survival compared
with blocking either alone, suggesting that the two molecules are part of the same pathway in MN
degeneration [108]. In stressed MNs, the upregulation of MAP4K4 leads to an increase in phospho-JNK
and phospho-c-Jun levels, with the subsequent increase of cleaved caspase3 levels and activation of the
canonical apoptotic pathway. Inhibition of MAP4K4 is able to reduce JNK and c-Jun phosphorylation
levels and decrease cell degeneration. Knocking down c-Jun also leads to MN number rescue. Neuritic
degeneration is an early event in neuronal disorders and often precedes MN death: SOD1-mutant
MNs in vitro show reduced neuritic length and number of nodes per MN, manifesting signs of
degeneration; inhibition of MAP4K4—and presumably of JNK—has a positive effect on neurite
outgrowth, by maintaining its structure and preventing neurons from degeneration [108].
Interestingly, MAPK-JNK is also involved in the regulation of autophagy, as its phosphorylation
causes a suppression of this critical intracellular pathway, which is essential for degrading aggregated
and misfolded proteins in cells, to support survival [109]. Wu and colleagues indicated that autophagy is
dysfunctional in ALS MNs, and MAP4K4 siRNA-mediated silencing induces a restoration of autophagic
physiological rate, potentially contributing to the reduction observed in mutant SOD1. This mechanism
seems not to be mediated by mTOR signaling, whereas it seems to be FoxO1 protein-dependent,
as phosphorylated FoxO1 levels increase after MAP4K4 inhibition, consistent with findings that JNK
deficiency increases FoxO1-mediated autophagy [108,110].
Together with MAP4K4, it has been proved that the dysregulation of transactive response
DNA-binding protein-43 (TDP-43) is linked to ALS pathogenesis, as an overexpression level of the
molecule has been found also in ALS patients. Increase in TDP-43 induces neuronal cell death through
the upregulation of JNK levels. The expression of a dominant- negative JNK, the administration
of JNK inhibitors, or dominant-negative c-Jun molecules reduces the TDP-43-mediated MN death
in vitro [111].
Moreover, it has been proved that the activation of the dual leucine zipper kinase (DLK) signaling
is detrimental in ALS, as well as in other neurodegenerative diseases like Alzheimer’s. Indeed, Le
Pichons and colleagues (2017) confirmed an age-dependent increase in phosphorylation of JNK and
c-Jun in neurons of the spinal cord (especially in lumbar portion) and in the cortex of SOD1G93A and
TDP-43A315T mutated ALS models, as well as in lysates from sALS patients, confirming the activation of
this pathway. By conditionally knocking-out the DLK gene, they revealed that DLK is required for the
activation of JNK pathway and phosphorylation of c-Jun in neurons, as the removal of DLK is able to
reduce the number of phospho-c-Jun positive cell in the spinal cord. DLK knock-out in the SOD1 model,
interestingly, is able to significantly reduce MN cell death in vivo, from 40% neuronal loss in ALS mice
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of 14 weeks of age to a 13%. Moreover, by DLK inhibition a significant rescue in axon lumen area is
observed in diseased mice, suggesting that the initial phase of axon degeneration is blocked or at least
delayed. Thus, DLK is involved in JNK pathway activation and subsequent neuronal death. Acting on
the DLK-JNK cascade could represent a promising neuroprotective approach: indeed, pharmacological
inhibition of DLK (i.e., using GNE-8505 or GNA-3511 molecules) reduces the number of phospho-c-Jun
positive cells in a dose dependent manner, delays neuromuscular junction denervation by almost 10%
and increases MNs survival in the spinal cord (13% of neuronal lost instead of 40% [112]).
Other studies highlighted the involvement of JNK pathway in ALS disease. Deep RNA sequencing
and gene expression profiling on iPS cell-based ALS models, followed by pharmacological screening,
identified about 480 genes in the SOD1 mutation dataset that were differentially regulated, compared
to control spinal cord. Among these molecules, ERK and JNK signaling have been highlighted as key
drivers of neurodegeneration in SOD1 MN progenitors in vitro: indeed, the ERK/JNK downstream
target AP1 complex member Jun (that has high-affinity for the AP-1 binding site in the Jun promoter
region inducing c-Jun transcription) is highly expressed in MNs compared with non-MN cells, providing
a mechanistic insight into the specific degeneration of MNs. Interestingly, this study revealed that the
MAPK pathway is altered also in FUS mutated-MNs, suggesting that network perturbations induced
by ALS converge partly on specific pathways [113].
Different strategies and pharmacological approaches designed to target JNKs and its upstream
or downstream molecules have been tested on ALS models to reduce MN death. Together with
pharmacological administration of molecular inhibitors, injections of viral genomes were used to easily
pass the blood brain barrier (BBB) and efficiently deliver genes in ALS mutant mice: for instance,
after delivering IGF1 genes in SOD1G93A, the increase in IGF1-positive MNs is observed in the
spinal cord, followed by an increase unbroken axon number, and reduction in neuroinflammation
(astrogliosis) and in muscular atrophy. IGF1 acts directly on both the stress activated JNK and p38
kinase pathways, remarkably decreasing their phosphorylation [114]. Knowing the identity of those
molecules upstream or downstream JNK that are dysregulated in ALS phenotypes may provide
biochemical markers to enable earlier diagnosis of the pathology and molecular targets for developing
new therapeutic compounds.
5.2. JNK Role in Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive MN disease, representing the most
common genetic cause of infant mortality. SMA is due to mutation/deletion in the survival motor
neuron 1 (SMN1) gene, and is characterized primarily by the degeneration of brainstem and spinal
cord MNs, that leads to skeletal muscle progressive denervation and atrophy, followed by symmetric
limb paralysis, respiratory failure, and finally death [115].
Indeed, the in vitro growth and differentiation of spinal cord MNs from SMA mice (SMN∆7) results
severely impaired compared with healthy MNs: neurons show growth defect and remarkable signs of
neurodegeneration (axonal thickening, retraction, and swelling) [116,117]. SMN deficiency may result
in intracellular stress that might activate intracellular signaling cascade and lead to neurodegeneration
in SMA.
Genabai and colleagues reported that JNK is actually required for MN degeneration.
They identified two MAPK signaling modules leading to full in vivo JNK activation in SMA: the
cascades ASK1/MKK4/7/JNK and MEKK1/MKK4/7/JNK are both activated in the spinal cord of the
SMA mouse model SMN∆7 and patients—with increased phosphorylation of JNKs, glycogen synthase
kinase 3 (GSK-3α and β), and ERK1—and mediate neuronal cell death caused by lower levels of
SMN expression in MNs. Gemin5, a part of the SMN complex, interacts with ASK1, MKK4, and JNK,
acting as a scaffold for the ASK1/MKK4/JNK signaling module to maintain the specificity of signaling.
The difference in the levels of activation of MKK4 compared to MKK7 might suggest a tight regulation
mechanism and specificity of the activation of the signaling modules [118,119].
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The levels of phosphorylated JNK are 2.6 fold during postnatal development in SMA mouse
spinal cord compared to wild-type condition, and in particular, among JNK isoforms, JNK3 is the
one modulating neurodegeneration in SMA. Indeed, by genetically knocking-out JNK3 in SMA mice,
the authors were able to perform a systemic rescue of the diseased phenotype, resulting in prevented
neurodegeneration and death of spinal cord MNs, and in increased skeletal muscle innervation with
subsequent reduction of atrophy and improvement of the overall growth Interestingly, the increase in
JNK phosphorylation in SMA mice is accompanied by the increase in phospho-c-Jun levels, suggesting
that the canonical apoptotic pathway (instead of other JNK-dependent pathways as ATF-2 recruitment)
is activated in SMA condition [118]. Moreover, a similar activation of JNK-c-Jun-mediated cell death
signaling cascade has been observed in a model of spinal muscular atrophy with respiratory distress
type 1 (SMARD-1), under control of HG kinase [120].
Thus, these results suggest that JNK activation occurs early in SMA, and continues to increase
with age, contributing to the increase in severity of the disease. JNK signaling pathway, by mediating
neurodegeneration through c-Jun activation, might represent a potential SMN-independent target of
intervention for the treatment of SMA (Figure 4B).
For this reason, recently, we pharmacologically inhibited the JNK cascade in SMA SMN∆7 mice, by
administering a cell-penetrating JNK inhibitor (named D-JNKI1) peptide of all the three isoforms [121].
This peptide has shown its efficacy in blocking JNK cascade and promoting neuroprotection in the
nervous system in both in vivo and in vitro studies [64,65,122–124]. In contiguity with Genabai
observations, in our work we confirmed that intracellular stress signaling pathway and apoptotic
mechanisms are increased in the SMA spinal cord, as the phosphorylation of JNK pathway is higher in
the later phase of SMA progression (postnatal age P12), compared with healthy mice of the same age.
SMA mice show less MNs compared to wild-type; moreover, many phospho-c-Jun positive MNs are
visible in SMA spinal ventral horns. The chronic pharmacological inhibition of JNK by D-JNKI1 is able
to strongly reduce phospho-c-Jun levels in MNs, showing its protective role. Indeed, after DJNKI-1
treatment, a significant reduction of MN neurodegeneration, inflammation, and muscular atrophy is
observed [125]. Thus, these data strongly support that, in SMN deficiency condition, JNK activation
is implied in MN degeneration and subsequent muscular atrophy. The inhibition of JNK signaling
pathway partially rescues SMA phenotype, by supporting the crosstalk between MNs and muscles,
as already observed for instance after the inhibition of the ROCK pathway [126].
Recently, a novel mechanism underlying JNK-dependent SMA MN degeneration has been
observed. Indeed, the zinc finger protein ZPR1 interacts with SMN protein and exerts a pro-survival
effect on MNs: ZPR1 is important for the accumulation of SMN in the nucleus; SMA patients
express lower levels of ZPR1 and the inhibition of the Zpr1 gene in SMA mutant mice increases the
severity of the pathology, with higher caspase-mediated neuron degeneration [127]. ZPR1-dependent
neurodegeneration has been linked with JNK activity: it has been discovered that deficiency of ZPR1
in the SMA spinal cord leads to the activation of the MLK3/MKK7/JNK cascade, with the consequent
phosphorylation of the c-Jun protein, followed by neuronal degeneration. This ZPR1-dependent
neuron degeneration mechanism is specifically mediated by JNK3 activation, as in ZPR1-deficient
degenerating neurons the MAPK array analysis shows only a small increase in JNK1 and JNK2
activation, in contrast with a marked increase (25-fold) in phospho-JNK3. Moreover, neurons derived
from Jnk3-knockout mice show reduced degeneration (21%) compared with degeneration (75%) of
wild-type neurons upon ZPR1 knockdown, confirming that loss of JNK3 markedly increases survival
(almost 54%) of neurons. Moreover, genetic ablation of JNK3 and pharmacological JNK inhibition
result in a reduction of phospho-c-Jun activity and reduced degeneration of ZPR1-deficient MNs.
Therefore, prevention of ZPR1 loss may help in reducing JNK-mediated MN degeneration, and data
confirm that JNK inhibition may be a viable therapeutic approach to delay or prevent MN degeneration
in SMA [128].
Thus, our and other studies suggest that the pharmacological inhibition of JNK pathway could
represent an effective potential adjuvant to other—already in use—SMN-dependent therapies for
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treating SMA disease (like the antisense oligonucleotides nusinersen, Biogen) [129] which constitute a
very promising strategy for SMA, but still have some limitations [130].
However contrasting results come from other papers, which conversely report no differences
in stress-activated JNK-c-Jun signaling in MNs of SMN∆7 SMA mice and SMA human spinal cord
compared to healthy tissue [131,132]. These inconsistencies can be ascribed to different time points
considered for the analyses. JNK and/or other (pro-apoptotic) molecular pathways can be activated
differently during the cell life: probably the analysis of their expression in MNs at later phases of
the disease (e.g., P16 in delta7 mouse model, as in [131]) might not reveal any differences in SMA
tissue, because at this stage the highest wave of MN degeneration has been already triggered and is
concluding. However further studies are necessary to clarify these aspects.
5.3. JNK Role in Spinal and Bulbar Muscular Atrophy
Spinal bulbar muscular atrophy (SBMA) is a hereditary late-onset neurodegenerative disorder,
which involves the expansion of the polyQ stretch in the androgen receptor (AR) [133]. SBMA
is a lower MN disease, characterized by degeneration of cells in both spinal cord and brainstem,
leading to proximal muscle weakness, muscle flaccidity, and atrophy [134]. This suggests that cellular
processes particularly critical for MN survival and functions are selectively altered by polyQ-AR
accumulation, even though the pathogenic mechanisms for SBMA remain unclear and no effective
treatments are available.
Similarly to other MN diseases, JNK pathway is activated also in SBMA. Indeed, the accumulation
of polyQ-AR neurotoxic fragments in neuronal cytoplasm results in caspase-dependent apoptotic cell
death, which requires the activation of JNK pathway through phosphorylation of c-Jun [135,136].
The MNs affected in SBMA (located in the brainstem and spinal cord) have some of the longest
axons in humans: such features render these cells particularly vulnerable to alteration in fast axonal
transport (FAT). In vitro studies demonstrated that polyQ-AR expression induces FAT inhibition
through a pathway involving JNK activation independently of hormone binding, the subsequent
phosphorylation of kinesin-1 heavy chain (KHC) subunits by JNK, and the inhibition of kinesin-1
binding to microtubules [133], leading to progressive cell death.
Moreover, also JNK-dependent nuclear export of PolyQ-AR is impaired in SBMA neurons [137].
Although the molecular mechanism by which polyQ-AR increases JNK activity has not been well
addressed yet, the increase in JNK activity in SBMA conditions, together with the inhibition of FAT
by polyQ-AR expression, may represent a primary pathogenic event to produce this dying-back
neuropathy. Thus, inhibiting JNK pathway to increase FAT in MNs could represent a favorable
therapeutic target [133].
6. Conclusions and Perspectives
The concept to improve neuroprotection through inhibition of JNK isoforms is driving the
search for specific drugs since many years. Despite that the efforts are in the directions to develop
isoform-specific JNK inhibitors for CNS disorders, JNK inhibitors that do not discriminate well between
JNK isoforms (e.g., DKJNI-1) demonstrate the most effective neuroprotection in vivo [138], consistent
with the idea that all the JNK isoforms contribute to neuronal death. To selectively block the effect
of JNK in the nucleus, the cytoplasm and the mitochondria, compartment-specific molecules against
the pro-apoptotic JNK effects have been generated, by fusing a nuclear export sequence or a nuclear
localization sequence upstream of the JNK inhibitor JBD domain. The nuclear localization sequence
provides substantial protection from cell death, suggesting that the nucleus is the major cellular
compartment in which JNK triggers death responses [27,139]. Thus, targeting JNK either in the nucleus
or in mitochondria may confer neuroprotection and represent a promising therapeutic approach
(reviewed in [18]).
JNK is an active key player in both the developing and adult brain, and exerts different
roles depending on the cell compartment, age, and cellular condition. Alteration of JNK pathway
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during development leads to defects in axonal architecture and pathfinding; whereas in adulthood,
the activation at several levels of JNK upstream and downstream pathways has been related to cell
death, degeneration, and MN pathologies. However, a complete view of how JNKs coordinate all these
events is lacking, and many new substrates of JNKs remain to be identified. Thus, understanding
the mechanisms underlying all JNK functions would be extremely important, in order to act on these
specific mechanisms to prevent cell death (as in case of neurodegenerative diseases as ALS, SMA,
or SBMA), or, on the contrary, to promote axonal regeneration and cell integrity after injury.
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